Vaxcyte (PCVX) Projected to Post Quarterly Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is expected to issue its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the firm earned ($1.10) EPS. On average, analysts expect Vaxcyte to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vaxcyte Trading Up 1.2%

NASDAQ:PCVX opened at $45.28 on Friday. The company has a 50-day moving average price of $36.99 and a 200-day moving average price of $34.63. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $116.00. The stock has a market cap of $5.88 billion, a price-to-earnings ratio of -11.02 and a beta of 1.12.

Analyst Upgrades and Downgrades

PCVX has been the subject of several research analyst reports. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and an average price target of $106.25.

Institutional Trading of Vaxcyte

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC increased its stake in Vaxcyte by 4.1% during the 2nd quarter. Hsbc Holdings PLC now owns 19,216 shares of the company’s stock valued at $628,000 after purchasing an additional 755 shares in the last quarter. Cetera Investment Advisers increased its stake in Vaxcyte by 13.8% during the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after purchasing an additional 932 shares in the last quarter. Nebula Research & Development LLC increased its stake in Vaxcyte by 2.3% during the 2nd quarter. Nebula Research & Development LLC now owns 49,873 shares of the company’s stock valued at $1,621,000 after purchasing an additional 1,113 shares in the last quarter. Osaic Holdings Inc. increased its stake in Vaxcyte by 110.8% during the 2nd quarter. Osaic Holdings Inc. now owns 3,859 shares of the company’s stock valued at $128,000 after purchasing an additional 2,028 shares in the last quarter. Finally, Headlands Technologies LLC increased its stake in Vaxcyte by 12.2% during the 2nd quarter. Headlands Technologies LLC now owns 26,993 shares of the company’s stock valued at $878,000 after purchasing an additional 2,941 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.